Publication:
Brief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patients

dc.contributor.authorTajuelo, Ana
dc.contributor.authorCarretero, Octavio
dc.contributor.authorGarcia-Rios, Estefani
dc.contributor.authorLopez-Siles, Mireia
dc.contributor.authorCano, Olga
dc.contributor.authorVazquez-Alcaraz, Monica
dc.contributor.authorMas-Lloret, Vicente
dc.contributor.authorRodríguez-Goncer, Isabel
dc.contributor.authorLalueza, Antonio
dc.contributor.authorLópez-Medrano, Francisco
dc.contributor.authorJuan, Rafael San
dc.contributor.authorFernández-Ruiz, Mario
dc.contributor.authorAguado, José María
dc.contributor.authorMcConnell, Michael J
dc.contributor.authorPerez-Romero, Pilar
dc.contributor.funderFundación Mutua Madrileña
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderMinisterio de Ciencia e Innovación (España)
dc.contributor.funderRETICS-Investigación en Patología Infecciosa (REIPI-ISCIII) (España)
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España)
dc.contributor.funderComunidad de Madrid (España)
dc.contributor.funderUnión Europea. Fondo Social Europeo (ESF/FSE)
dc.contributor.funderPlan Nacional de I+D+i (España)
dc.date.accessioned2022-08-05T12:25:57Z
dc.date.available2022-08-05T12:25:57Z
dc.date.issued2022-04-25
dc.descriptionErratum for: Brief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patients. Tajuelo A, Carretero O, García-Ríos E, López-Siles M, Cano O, Vázquez M, Más V, Rodríguez-Goncer I, Lalueza A, López-Medrano F, Juan RS, Fernández-Ruiz M, Aguado JM, McConnell MJ, Pérez-Romero P. Front Immunol. 2022 Apr 25;13:878812. doi: 10.3389/fimmu.2022.878812. eCollection 2022. PMID: 35547738 Free PMC article.
dc.description.abstractIntroduction: There is robust evidence indicating that the SARS-CoV-2-specific humoral response is associated with protection against severe disease. However, relatively little data exist regarding how the humoral immune response at the time of hospital admission correlates with disease severity in unimmunized patients. Our goal was toidentify variables of the humoral response that could potentially serve as prognostic markers for COVID-19 progressionin unvaccinated SARS-CoV-2 patients. Methods: A prospective cross-sectional study was carried out in a cohort of 160 unimmunized, adult COVID-19 patients from the Hospital Universitario 12Octubre. Participants were classified into four clinical groups based on disease severity: non-survivors with respiratory failure (RF), RF survivors, patients requiring oxygen therapy and those not receiving oxygen therapy. Serum samples were taken on admission and IgM, IgG, IgG subclass antibody titers were determined by ELISA, and neutralizing antibody titersusing a surrogate neutralization assay. The differences in the antibody titers between groups and the association between the clinical and analytical characteristics of the patients and the antibody titers were analyzed. Results: Patients that developed RF and survived had IgM titers that were 2-fold higher than non-survivors (p = 0.001), higher levels of total IgG than those who developed RF and succumbed to infection (p< 0.001), and than patients who required oxygen therapy (p< 0.05), and had 5-fold higher IgG1 titers than RF non-survivors (p< 0.001) and those who needed oxygen therapy (p< 0.001), and 2-fold higher than patients that did not require oxygen therapy during admission (p< 0.05). In contrast, RF non-survivorshad the lowest neutralizing antibodylevels, which were significantly lower compared those with RF that survived (p = 0.03). A positive correlation was found between IgM, total IgG, IgG1 and IgG3 titers and neutralizing antibody titers in the total cohort (p ≤ 0.0036). Conclusions: We demonstrate that patients with RF that survived infection had significantly higher IgM, IgG, IgG1 and neutralizing titers compared to patients with RF that succumb to infection, suggesting that using humoral response variables could be used as a prognostic marker for guiding the clinical management of unimmunized patients admitted to the hospital for SARS-CoV-2 infection.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis work was supported by Mutua Madrileña Foundation (2020/0056) “Plan Nacional de I+D+I” and Instituto de Salud Carlos III (COVID-19 Research Call COV20/00181 and COV20_00679), Subdirección General de Redes y Centros de Investigación Cooperativa, Spanish Ministry of Science and Innovation, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016) - co-financed by the European Development Regional Fund (EDRF) and the European Social Fund (ESF) "A way to achieve Europe- The ESF invests in your future". Red de Enfermedades Infecciosas (CIBERINFEC), CB21/13/00079. EG-R is supported by the Sara Borrell Program (CD18CIII/00007), MLS is supported by the Sara Borrell Program (CD17CIIII/00017), Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades., and AT is supported by the Garantía Juvenil Program of the Comunidad Autonoma de Madrid. IRG holds a research training contract “Río Hortega” (CM19/00163) and MFR a research contract “Miguel Servet” (CP18/00073), both from the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation.es_ES
dc.format.page878812es_ES
dc.format.volume13es_ES
dc.identifier.citationFront Immunol. 2022 Apr 25;13:878812.es_ES
dc.identifier.doi10.3389/fimmu.2022.878812es_ES
dc.identifier.e-issn1664-3224es_ES
dc.identifier.journalFrontiers in Immunologyes_ES
dc.identifier.pubmedID35547738es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14872
dc.language.isoenges_ES
dc.publisherFrontiers Media
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MINECO//RD16%2F0016%2F0004/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS/es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/COV20/00679es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CB21/13/00079es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CD18CIII/00007es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CD17CIIII/00017es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CM19/00163es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CP18/00073es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/COV20/00181es_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fimmu.2022.878812es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCOVID disease severityes_ES
dc.subjectIgGes_ES
dc.subjectIgM 2es_ES
dc.subjectSARS-CoV-2es_ES
dc.subjectHumoral responsees_ES
dc.subject.meshCOVID-19es_ES
dc.subject.meshRespiratory Insufficiencyes_ES
dc.subject.meshAdultes_ES
dc.subject.meshAntibodies, Neutralizinges_ES
dc.subject.meshAntibodies, Virales_ES
dc.subject.meshCross-Sectional Studieses_ES
dc.subject.meshHumanses_ES
dc.subject.meshImmunity, Humorales_ES
dc.subject.meshImmunoglobulin Ges_ES
dc.subject.meshImmunoglobulin Mes_ES
dc.subject.meshOxygenes_ES
dc.subject.meshProspective Studieses_ES
dc.subject.meshResearch Reportes_ES
dc.subject.meshSARS-CoV-2es_ES
dc.titleBrief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patientses_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication78ddc608-8ded-4d2f-bb25-ec2792783993
relation.isAuthorOfPublication50b540df-28b6-4182-a1ee-d7ee50b0114e
relation.isAuthorOfPublication56aad11f-59aa-480b-ade4-8b7200f31d08
relation.isAuthorOfPublication05b142a5-2280-41d5-8af9-1119c5338244
relation.isAuthorOfPublication4f567393-69b2-45f3-8951-778808a00edc
relation.isAuthorOfPublicationcdaece7c-45bc-4988-bb11-429e0b25402b
relation.isAuthorOfPublication1d2e9ea7-be75-4b13-a09e-656f8f304a14
relation.isAuthorOfPublication619c44d6-0adf-4ccf-9b6a-66663bad5429
relation.isAuthorOfPublication.latestForDiscovery78ddc608-8ded-4d2f-bb25-ec2792783993
relation.isFunderOfPublication965c36a0-b77d-4aed-b64e-2bca07b473e6
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication289dce42-6a28-4892-b0a8-c70c46cbb185
relation.isFunderOfPublication59c823cb-42b5-4b1b-a401-bf53ee82c170
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublication1aef4c3b-1ee5-4534-83b4-3f3811c67280
relation.isFunderOfPublicationc87c70a3-e023-4b6b-ac25-1b2d1b483786
relation.isFunderOfPublication36ca2ebf-c6c3-4f53-8618-500af224a277
relation.isFunderOfPublication0e5401ef-8ce7-439f-85e0-4e3550b5fade
relation.isFunderOfPublication.latestForDiscovery965c36a0-b77d-4aed-b64e-2bca07b473e6
relation.isPublisherOfPublication9f9fa5ea-093b-43d8-bf2c-5bd65d08a802
relation.isPublisherOfPublication.latestForDiscovery9f9fa5ea-093b-43d8-bf2c-5bd65d08a802

Files

Original bundle

Now showing 1 - 3 of 3
Loading...
Thumbnail Image
Name:
BriefResearchReportVirus_2022.pdf
Size:
2.03 MB
Format:
Adobe Portable Document Format
Description:
Artículo principal
Loading...
Thumbnail Image
Name:
BriefResearchReportVirusSupplementaryMaterial_2022.pdf
Size:
680.53 KB
Format:
Adobe Portable Document Format
Description:
Supplementary Information
Loading...
Thumbnail Image
Name:
CorrigendumBriefResearchReport_2022.pdf
Size:
181.73 KB
Format:
Adobe Portable Document Format
Description:
Coprrección de errores